Cargando…
Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546425/ https://www.ncbi.nlm.nih.gov/pubmed/26295570 http://dx.doi.org/10.1371/journal.pone.0136515 |
| _version_ | 1782386926357053440 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4546425 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-45464252015-09-01 Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA PLoS One Correction Public Library of Science 2015-08-21 /pmc/articles/PMC4546425/ /pubmed/26295570 http://dx.doi.org/10.1371/journal.pone.0136515 Text en © 2015 The PLOS ONE Staff http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
| spellingShingle | Correction Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA |
| title | Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA |
| title_full | Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA |
| title_fullStr | Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA |
| title_full_unstemmed | Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA |
| title_short | Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA |
| title_sort | correction: treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the usa |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546425/ https://www.ncbi.nlm.nih.gov/pubmed/26295570 http://dx.doi.org/10.1371/journal.pone.0136515 |
| work_keys_str_mv | AT correctiontreatmentfrequencyanddosingintervalofranibizumabandafliberceptforneovascularagerelatedmaculardegenerationinroutineclinicalpracticeintheusa |